NCT01828619

Study of New RIC Regimen of BuFlu in Older and/or Intolerable Patients

The Study of New RIC Regimen of BuFlu in Older or Intolerable Patients With Hematologic Malignant Diseases

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 60 (estimated)
• Sponsor: Peking University People's Hospital · Academic / Other
• Sex: All
• Age: 55 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether the new RIC regimen, containing of low dose of Bu (9.6mg/kg)and fludarabine without ATG, is suitable and effective in treating aged and/or intolerable patients with hematologic malignant disease, who undergoes allogenic stem cell transplantation.

Conditions

• Leukemia
• Myelodysplastic Syndrome

Interventions

Type	Name	Description
PROCEDURE	modified BuFlu conditioning	The regimen consisted of hydroxyurea 80 mg/kg on d -10; cytorabine 2 g/m2 on d -9; busulfan 3.2mg/kg/day iv. ×3days( on d -8 to -6); Flu30mg/m\^2 i.v.×5days(on d-6 to-2) and semustine 250 mg/m2 on d -3.

Timeline

• Start date: 2013-02-01
• Primary completion: 2015-12-01
• First posted: 2013-04-10
• Last updated: 2013-04-10

Locations

1 site across 1 country: China